

Search

EN

iShares Health Innovation Active ETF (BMED) Latest News, Market Updates & Sentiment | Edgen

Back

iShares Health Innovation Active ETF (BMED)

BMED Stock Price Chart

BMED

iShares Health Innovation Active ETF

$28.39

-0.26%

$-0.07

At close: Mar 24, 16:00:00 GMT-4

$28.39

0%

$0

Pre-market: Mar 25, 08:14:59 GMT-4

Overview Forecast Holdings News

Key Stats

Prev.Close

$28.46

Open

$28.24

Day's Range

$28.24 - $28.41

52 week range

$20.57 - $32.18

Volume

3.0K

Avg.Volume

4.7K

Dividend yield

--

Net Assets

$0

NAV

--

Expense Ratio

--

Shares Outstanding

357.5K

What is BMED?

BMED was created on 2020-09-29 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 10.38m in AUM and 44 holdings. BMED is actively managed to invest in global equities in the health sciences industry.

Features

AI Copilot for Stock & Crypto

Price Prediction

Fundraise Tracker

Crypto Comparison

Resources

Market

Terms of Use Privacy Policy Sitemap

© 2026 Finture Development Limited. All rights reserved

Merck Nears $6 Billion All-Cash Deal for Terns Pharma

Merck Nears $6 Billion All-Cash Deal for Terns Pharma

Mar 25 2026, 01:41

Mar 24 2026, 00:00

Gilead Advances Talks to Acquire Ouro Medicines

Gilead Advances Talks to Acquire Ouro Medicines

Mar 23 2026, 16:52

TuHURA Hires JNJ Veteran Behind $16B Drugs for Cancer Push

TuHURA Hires JNJ Veteran Behind $16B Drugs for Cancer Push

Mar 23 2026, 12:06

AbbVie Stock Falls 5% as FDA Approves J&J's Rival Psoriasis Pill

AbbVie Stock Falls 5% as FDA Approves J&J's Rival Psoriasis Pill

Mar 19 2026, 13:42

Johnson & Johnson Secures FDA Approval for Oral Psoriasis Drug

Johnson & Johnson Secures FDA Approval for Oral Psoriasis Drug

Mar 18 2026, 12:07

FDA Approves J&J, Halozyme Myeloma Combination Therapy

FDA Approves J&J, Halozyme Myeloma Combination Therapy

Mar 06 2026, 13:28

Johnson & Johnson Launches Direct-to-Consumer Drug Sales

Johnson & Johnson Launches Direct-to-Consumer Drug Sales

Mar 04 2026, 23:32

Tempus AI Partners With Merck to Accelerate AI-Driven Medicine

Tempus AI Partners With Merck to Accelerate AI-Driven Medicine

Mar 03 2026, 13:49

J&J Lupus Drug Nipocalimab Wins FDA Fast Track Status

J&J Lupus Drug Nipocalimab Wins FDA Fast Track Status

Mar 03 2026, 13:13

Merck's KEYTRUDA Trial Shows Survival Gain in Ovarian Cancer

Merck's KEYTRUDA Trial Shows Survival Gain in Ovarian Cancer

Feb 27 2026, 15:36

Merck HIV Drug Matches Gilead Top-Seller in Trial as Keytruda Patent Cliff Looms

Merck HIV Drug Matches Gilead Top-Seller in Trial as Keytruda Patent Cliff Looms

Feb 25 2026, 20:33

Gilead's HIV Drug Succeeds in Phase 3 Trials

Gilead's HIV Drug Succeeds in Phase 3 Trials

Feb 25 2026, 19:08

Merck Sets Stage for High-Stakes HIV Drug Data at CROI 2026

Merck Sets Stage for High-Stakes HIV Drug Data at CROI 2026

Feb 25 2026, 18:11

Johnson & Johnson Targets AbbVie With $32B R&D Bet

Johnson & Johnson Targets AbbVie With $32B R&D Bet

Feb 23 2026, 14:31

J&J Wins EU Approval for Faster Lung Cancer Drug

J&J Wins EU Approval for Faster Lung Cancer Drug

Feb 23 2026, 13:29

Gilead to Acquire Biotech Firm for 80% Premium

Gilead to Acquire Biotech Firm for 80% Premium

Feb 23 2026, 11:59

Merck Creates Cancer Unit To Battle Key Patent Expiration

Merck Creates Cancer Unit To Battle Key Patent Expiration

Feb 23 2026, 11:33